Is telbivudine effective for the treatment of HBeAg-positive hepatitis B (HBV) (Hep B)?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

The results of the phase III GLOBE Trial that tested the administration of 600 mg of telbivudine versus 100 mg of 3TC over a 2-year period showed that in the HBeAg-positive population, therapeutic response (defined as HBV DNA < 10,000 copies/mL, with either ALT normalization or HBeAg loss) was 75% for the patients treated with telbivudine and 67% for the patients treated with 3TC. [73, 74]

Of the patients receiving telbivudine, 26% lost the e antigen, versus 23% of the patients receiving 3TC. [73, 74]  In addition, a 6.5-log reduction of the HBV DNA was noted for the patients receiving telbivudine versus a 5.5-log reduction for the patients receiving 3TC.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!